IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2004;45:2438-2446.)
© 2004 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.03-0805
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, P.
Right arrow Articles by Jaffe, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, P.
Right arrow Articles by Jaffe, G. J.

Effect of NF-{kappa}B Inhibition on TNF-{alpha}–Induced Apoptosis in Human RPE Cells

Ping Yang,1 Brian S. McKay,1,2 Janice B. Allen,3,4 and Glenn J. Jaffe1

1From the Departments of Ophthalmology and 2Cell Biology, Duke University Medical Center, Durham, North Carolina; and the 3Comparative Ophthalmology Research Laboratories, North Carolina State University, Raleigh, North Carolina.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
PURPOSE. In many cell types, tumor necrosis factor (TNF)-{alpha}–induced apoptosis is prevented by production of TNF-{alpha}–induced antiapoptotic protein, a process mediated by nuclear transcription factor (NF)-{kappa}B. TNF-{alpha} is widely expressed in proliferative vitreoretinopathy (PVR) membranes and is present in the vitreous of eyes with PVR. To understand mechanisms responsible for RPE cell survival and death in this disease, this study was conducted to determine whether specific NF-{kappa}B blockade by mutant inhibitory (I)-{kappa}B (I{kappa}B) affects TNF-{alpha}–induced cell death.

METHODS. Cultured human RPE cells and T-98G cells were infected with adenovirus encoding either ß-galactosidase or mutant I{kappa}B and then treated with TNF-{alpha} or interleukin (IL)-1ß. I{kappa}B, inhibitor of apoptosis protein (IAP)-1, and cellular Fas-associated death domain–like interleukin-1ß–converting enzyme-like inhibitory protein (c-FLIP) expression was determined by Western blot. Functional NF-{kappa}B activation was examined by luciferase reporter assay. Cell viability was evaluated by trypan blue exclusion assay. Caspase-3 activity and DNA fragmentation was measured with an enzyme-linked immunosorbent assay.

RESULTS. Mutant I{kappa}B expression blocked cytokine-induced I{kappa}B degradation and NF-{kappa}B transcriptional activity in RPE cells and T-98G cells. RPE cells were resistant to TNF-{alpha}–induced apoptosis, even after NF-{kappa}B activation was specifically blocked. In contrast, TNF-{alpha} dramatically induced apoptosis in T-98G cells after NF-{kappa}B inhibition. c-IAP1 expression was not affected by TNF-{alpha} or mutant I{kappa}B, and mutant I{kappa}B abolished TNF-{alpha}–induced c-FLIP induction in RPE cells.

CONCLUSIONS. RPE cells are resistant to TNF-{alpha}–induced cell death, even after NF-{kappa}B activation is specifically blocked. RPE cell resistance to apoptotic signals present in eyes with PVR, mediated by survival factors such as c-FLIP and c-IAP1, may help to explain unwanted and unchecked cell proliferation in this disease.

Proliferative vitreoretinopathy (PVR) remains the principal cause for the failure of retinal reattachment surgery and is a potentially blinding disease. PVR is characterized by uncontrolled cell proliferation and migration into the subretinal space and vitreous cavity and onto the retinal surface and undersurface.1 2 Cell-mediated contraction of the fibrocellular scar causes traction on the retina, leading to retinal detachment and subsequent loss of vision.3

Apoptosis is a form of programed cell death that plays a fundamental role in many normal biological processes, as well as in diseases such as PVR and age-related macular degeneration (AMD).4 5 The targeted induction of apoptosis is a novel therapeutic approach to control the unlimited growth of proliferating cells.6

Tumor necrosis factor (TNF)-{alpha}, originally described for its antitumor activity, is widely expressed in PVR membranes7 8 and choroidal neovascular membranes (CNVMs)9 and is present in the vitreous of eyes with PVR.7 10 11 Retinal pigment epithelial (RPE) cells are found in surgically removed PVR epiretinal membranes1 12 13 and CNVMs.9 RPE cell proliferation is thought to contribute to membrane formation in PVR.1 12 13 TNF-{alpha} is a major regulator of RPE activation responses, including cell attachment, spreading, chemotaxis, migration, and proliferation.14 15

Nuclear transcription factor (NF)-{kappa}B is a pivotal regulator of many different genes, including multiple inflammatory cytokine genes and apoptosis-related genes.16 In many cells types, TNF-{alpha}–induced apoptosis is prevented by parallel TNF-{alpha}–induced production of antiapoptotic proteins, such as cellular inhibitor of apoptosis protein (c-IAP) and cellular Fas-associated death domain (FADD)-like interleukin-1ß-converting enzyme-like inhibitory protein (c-FLIP), a process mediated by NF-{kappa}B.17 18 19 20 RPE cells are normally resistant to TNF-{alpha}–mediated apoptosis, and in fact proliferate in response to this cytokine.15 NF-{kappa}B inhibition results in apoptosis in a variety of cell types originally resistant to TNF-{alpha}–induced apoptosis, implying anti-NF-{kappa}B therapies could be a new tool for the treatment of inflammatory diseases and cancers.21 22 23 24 However, the effect of specific NF-{kappa}B inhibition on RPE cell apoptosis is unknown. To understand mechanisms responsible for RPE cell survival and death in PVR, we transduced a NF-{kappa}B super-repressor, a mutant form of the inhibitor {kappa}B (I{kappa}B) gene with substitutions by alanine at serines 32 and 36, into human RPE cells to determine whether specific NF-{kappa}B inhibition affects TNF-{alpha}–induced RPE cell apoptosis.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Cell Culture
Human donor eyes were obtained from the North Carolina Organ Donor and Eye Bank, in accordance with the provisions of the Declaration of Helsinki for research involving human tissue. RPE cells were harvested from eyes, as previously described.25 T-98G glioma cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). These cells were chosen as a positive control because they are known to express TNF receptor (TNF-R)126 and are sensitive to TNF-{alpha}–induced apoptosis after NF-{kappa}B blockade.23 Cells were grown in Eagle’s minimum essential medium (MEM; Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT) and 1x antibiotic–antimycotic (Invitrogen) at 37°C in a humidified environment containing 5% CO2.

Detection of LacZ Expression
To determine transduction efficiency, cells were infected with an adenovirus encoding ß-galactosidase (LacZ) at a variety of multiplicities of infection (MOIs) ranging from 10 to 300. Forty-eight hours after infection, LacZ expression was examined by staining the cells with 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-gal) solution. Blue cell staining was detected by phase-contrast microscopy. A masked observer determined the percentage of cells with blue staining in each of three microscopic fields (200x).

Adenoviral Infection and Stimulation
RPE cells or T-98G cells (1 x 105) were seeded in six-well plates (Costar, Corning Inc., Corning, NY). Twenty-four hours later, cells were incubated with fresh medium for an additional 24 hours. Cells were infected with adenovirus encoding either LacZ or mutant I{kappa}B27 (University of North Carolina at Chapel Hill Gene Delivery Core, Chapel Hill, NC) in MEM containing 1% FBS (RPE cell MOI = 10, T-98G cell MOI = 300). Twenty-four hours later, cells were treated for various times with TNF-{alpha} (1.1 x 103 U/mL; R&D Systems Inc., Minneapolis, MN) or IL-1ß (5 U/mL; Becton Dickinson Labware, Bedford, MA) in MEM containing 1% FBS. We chose IL-1ß and TNF-{alpha} concentrations that we have shown to stimulate cytokine gene expression and cause I{kappa}B degradation in RPE cells.28 29

Cell Extracts and Western Blot
Cells in duplicate wells were stimulated with TNF-{alpha} or IL-1ß for various times. After the medium was removed, the cells were washed twice with cold Hanks’ balanced salt solution and lysed with RIPA buffer (50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor cocktail (Roche, Indianapolis, IN). Lysates were transferred to 1.5-mL microcentrifuge tubes and cleared by centrifugation. Total protein in the supernatants was measured by the Bradford assay (Bio-Rad, Hercules, CA) with bovine serum albumin (BSA) used to generate the curve, according to the manufacturer’s instructions. Protein (20 µg) was electrophoresed on a 12.5% SDS-polyacrylamide gel overlaid with a 3.6% polyacrylamide stacking gel. The proteins were transferred to nitrocellulose membrane (Bio-Rad) using a mini-transblot apparatus (Bio-Rad) according to the manufacturer’s directions. Transfers were performed overnight at room temperature (RT). Nonspecific binding sites were blocked by immersing the membrane in 10% fat-free milk powder (SACO Foods Inc, Middleton, WI) for 60 minutes at RT. The blocking step was repeated, and then membranes were washed three times (5 minutes per wash) in Tris-buffered saline containing 0.1% Tween-20 (TBST). The membranes were incubated overnight with rabbit polyclonal antibody directed against I{kappa}B (1:2000 in 5% milk; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal antibody against c-IAP1 (1:2000 in 5% milk; Santa Cruz Biotechnology) and mouse monoclonal antibody against c-FLIP NF6 (1:500 in 5% milk; Alexis, San Diego, CA) at 4°C. The blots were then washed three times (20 minutes per wash) in TBST and incubated with anti-rabbit IgG conjugated with horseradish peroxidase (1:5000 in 5% milk; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) or anti-mouse IgG conjugated with horseradish peroxidase (1:2500 in 5% milk; Jackson ImmunoResearch Laboratories) at 4°C for 60 minutes. Immunoreactive bands were visualized using an enhanced chemiluminescence (ECL) detection kit (Amersham Pharmacia Biotech, Piscataway, NJ).

Transfection and NF-{kappa}B–Driven Luciferase Reporter Assay
Transfection was performed with a lipophilic reagent (LipoTAXI; Stratagene, La Jolla, CA) according to the manufacturer’s recommendations. Briefly, cells in triplicate wells were washed twice with 3 mL of serum-free, antibiotic-free MEM (MEM-SA) and incubated in MEM-SA at 37°C for 15 minutes. Plasmid DNA (5 µg) encoding firefly luciferase downstream from the NF-{kappa}B promoter (Stratagene) and 1 µg of DNA encoding a constitutively expressed Renilla luciferase gene (Promega, Madison, WI) were mixed with the transfection reagent and then added to cell cultures in MEM–SA medium. After a 4-hour incubation, 3 mL of 10% FBS-MEM was added to each well. Cells were re-fed 24 hours after transfection and maintained in fresh 10% FBS-MEM for another 24 hours before infection. Cells were stimulated with TNF-{alpha} or IL-1ß for 4 hours. NF-{kappa}B-luciferase reporter assay was performed with a luciferase reporter assay kit (Dual-Luciferase Reporter Assay System; Promega) according to the manufacturer’s instructions. Firefly luciferase activity and Renilla luciferase activity in the supernatants were measured with a luminometer (LB 9501, EG&G Berghold, Bundoora, Australia), and the ratio of firefly luciferase activity to Renilla luciferase activity was calculated.

Assessment of Cell Number
Cells in triplicate wells were stimulated with TNF-{alpha} for various times. After the medium was removed, cells were washed with PBS and trypsinized. Cell viability was determined with a trypan blue exclusion assay. Live cells that excluded 0.2% trypan blue dye were counted with a hemocytometer.

Detection of Caspase-3 Activity and DNA Fragmentation
Cells in triplicate wells were stimulated with TNF-{alpha} or IL-1ß for 8 hours. They were harvested by lysis in buffers provided in caspase-3 and DNA fragmentation kits, respectively, as described later. Lysates were transferred to tubes and cleared by centrifugation. Caspase-3 activity, an early marker of apoptosis,30 31 and DNA fragmentation, a late marker of apoptosis, were quantified by enzyme-linked immunosorbent assay (ELISA; caspase-3 activity kit: BD Biosciences-Clontech, Palo Alto, CA; DNA fragmentation kit: Roche) according to the manufacturers’ instructions.

Statistical Analysis
Data are expressed as the mean ± SD. Student’s t-test was used to determine whether there were statistically significant differences between treatment groups determined by luciferase assay, the number of cells, caspase-3 activity, or DNA fragmentation assay. P < 0.05 was considered to be statistically significant. More than five different experiments were performed with Western blot to show that overexpression of mutant I{kappa}B was resistant to cytokine-induced I{kappa}B degradation. Assessment of cell number was performed in triplicate and was repeated four times with RPE cells from three different donors. The luciferase reporter assay, a functional assay of NF-{kappa}B activation and caspase-3 activity was performed in triplicate and was repeated two times with RPE cells from two different donors. The DNA fragmentation assay, performed in triplicate was repeated two times. Western blot on duplicate samples from each treatment group was performed once to determine c-FLIP and c-IAP1 expression.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Determination of Transduction Efficiency
We have previously reported that an MOI of 10 with the present adenoviral vector was optimal to block NF-{kappa}B activation by mutant I{kappa}B in RPE cells.29 With this information, we compared LacZ transduction efficiency in RPE cells to that in T-98G cells by X-gal assay. The percentage of RPE cells infected with adenovirus encoding LacZ at an MOI of 10 was 95%. The percentage in T-98G cells at MOI of 10, 50, 150, and 300 was 30%, 40%, 70%, and 80%, respectively, indicating that there was greater transduction efficiency in RPE cells. We also examined mutant I{kappa}B adenoviral infection efficiency in T-98G cells by Western blot. The expression of mutant I{kappa}B protein was increased in an MOI-dependent manner in T-98G cells (Fig. 1) . Based on our previous studies,29 our current results, and T-98G cell transduction efficiency reported previously,23 we chose an MOI of 10 in RPE cells and of 300 in T-98G cells for subsequent experiments.



View larger version (85K):
[in this window]
[in a new window]
  		FIGURE 1. Detection of LacZ and mutant I{kappa}B expression. (A) RPE cells and T-98G cells were infected with an adenovirus containing LacZ at different MOIs. Forty-eight hours after infection, the expression of the LacZ transgene was examined by staining the cells with X-gal. (B) T-98G cells in duplicate wells were infected with adenovirus containing mutant I{kappa}B at different MOIs. One day after infection, the expression of the mutant I{kappa}B transgene was examined by Western blot. Bands at 45 kDa correspond to mutant I{kappa}B transgene and bands at 37 kDa to endogenous I{kappa}B. (C) Blot in (B) stripped and reprobed with antibody to ß-catenin, a control for gel loading.

 
Resistance to Cytokine-Stimulated I{kappa}B Degradation by Mutant I{kappa}B Overexpression
We have reported that RPE cells that overexpress mutant I{kappa}B are resistant to IL-1ß–induced I{kappa}B degradation.29 To evaluate the effect of mutant I{kappa}B transgene on TNF-{alpha}–induced I{kappa}B degradation in RPE cells and on TNF-{alpha}– and IL-1ß–induced I{kappa}B degradation in T-98G cells, I{kappa}B protein expression was determined by Western blot analysis. When RPE cells were treated with TNF-{alpha} or T-98G cells were treated with TNF-{alpha} or IL-1ß, endogenous I{kappa}B protein was degraded within 30 minutes (Figs. 2A 2B 2C) . In contrast, mutant I{kappa}B was not degraded after cytokine treatment. Endogenous I{kappa}B degradation was variable, despite constant overexpression of mutant I{kappa}B, a finding that we have observed previously.29 As a control for cytoplasmic phosphorylation and degradation we chose ß-catenin, a protein that is phosphorylated and degraded by the proteasome in response to an NF-{kappa}B–independent signal-transduction pathway.32 In contrast to I{kappa}B, ß-catenin was not degraded in response to cytokine stimulation in noninfected cells, LacZ-expressing cells, or cells infected to express mutant I{kappa}B (Figs. 2D 2E 2F) . Accordingly, ß-catenin also serves as an excellent protein to standardize protein loading (also see Fig. 1C ).



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 2. Resistance to cytokine-induced I{kappa}B degradation by mutant I{kappa}B overexpression. RPE cells and T-98G cells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were treated with medium alone, TNF-{alpha} (1.1 x 103 U/mL), or IL-1ß (5 U/mL) for 30 minutes, and cytoplasmic proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane for Western blot analysis. (A–C) Western blot probed with antibody to I{kappa}B. Bands at 45 kDa correspond to mutant I{kappa}B transgene and bands at 37 kDa to endogenous I{kappa}B. The relative quantities of endogenous and mutant I{kappa}B proteins, determined by densitometry, are shown separately below each lane. (D–F) Blots in (A), (B), and (C), respectively, separately stripped and reprobed with antibody to ß-catenin, a control for gel loading. The relative quantity of ß-catenin protein is shown below each lane.

 
Inhibition of Cytokine-Induced NF-{kappa}B Transcriptional Activity by Overexpression of Mutant I{kappa}B
After I{kappa}B degradation, NF-{kappa}B is translocated to the nucleus, binds to DNA and activates gene transcription. We have shown previously that expression of mutant I{kappa}B protein blocks IL-1ß–induced NF-{kappa}B transcriptional activity in RPE cells.29 In the current study, we used a dual-luciferase reporter system to determine the effect of mutant I{kappa}B on TNF-{alpha}–induced NF-{kappa}B transcriptional activity in RPE cells and its effect on TNF-{alpha}– and IL-1ß–induced transcriptional activity in T-98G cells. TNF-{alpha} significantly induced NF-{kappa}B–driven luciferase activity in LacZ-expressing RPE cells and T-98G cells. A similar effect was observed in IL-1ß–treated T-98G cells. Basal and cytokine mediated NF-{kappa}B transcriptional activity was significantly suppressed in both cell types when infected to express mutant I{kappa}B (Fig. 3) .



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 3. Inhibition of NF-{kappa}B transcriptional activity by mutant I{kappa}B overexpression. RPE cells in triplicate wells were cotransfected with 5 µg plasmid DNA encoding firefly luciferase driven by the NF-{kappa}B promotor and 1 µg of DNA encoding a constitutively expressed Renilla luciferase gene. The firefly luciferase plasmid contains a luciferase reporter gene driven by a tandem repeat of NF-{kappa}B binding elements and therefore serves as an experimental reporter of NF-{kappa}B activation. Renilla luciferase serves as the control reporter to normalize the activity of the experimental reporter based on transfection efficiency and cell viability. Two days after transfection, the cells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were exposed to medium alone, TNF-{alpha} (1.1 x 103 U/mL) or IL-1ß (5 U/mL) for 4 hours. Cells were harvested, and lysates were tested for luciferase activity using a dual-luciferase assay system. Relative luminescence denotes the ratio of firefly luciferase activity (NF-{kappa}B-dependent) to Renilla luciferase (control) activity to standardize for transfection efficiency. Results are expressed as mean ± SD (n = 3). *P < 0.002 versus untreated cells; **P < 0.0001 versus TNF-{alpha}–treated cells in the LacZ virus group; #P < 0.0003 versus untreated cells in LacZ virus group; ##P < 0.00001 versus IL-1ß–treated cells in LacZ virus group.

 
Resistance to TNF-{alpha}–Induced Apoptosis in RPE Cells that Overexpress Mutant I{kappa}B
In many cells, TNF-{alpha}–induced NF-{kappa}B activation leads to antiapoptotic protein production.17 18 19 20 TNF-{alpha}–induced proteins protect cells from TNF-{alpha}–driven caspase activity and apoptosis. To determine whether NF-{kappa}B activation protects RPE cells from TNF-{alpha}–induced apoptosis, we examined the effect of NF-{kappa}B blockade on RPE cell number, caspase-3 activity, and DNA fragmentation in the presence and absence of TNF-{alpha}. RPE cells infected either with LacZ virus or mutant I{kappa}B virus with or without 24-hour TNF-{alpha} treatment appeared healthy. However, TNF-{alpha} treatment induced a marked increase in T-98G cell death when cells were infected with an adenovirus encoding mutant I{kappa}B, but not when they were infected by an adenovirus encoding LacZ. T-98G cells infected to express mutant I{kappa}B were rounded, detached from plates, and floated in the medium at 24 hours after TNF-{alpha} stimulation (Fig. 4) . IL-1ß had no effect on RPE cell or T-98G cell morphology regardless of whether cells were not infected, infected with adenovirus encoding LacZ, or infected with adenovirus encoding mutant I{kappa}B.



View larger version (105K):
[in this window]
[in a new window]
  		FIGURE 4. Effect of mutant I{kappa}B overexpression on TNF-{alpha}–induced cell death. RPE cells and T-98G cells were infected with adenovirus containing mutant I{kappa}B. One day after infection, cells were treated with TNF-{alpha} (1.1 x 103 U/mL) for 24 hours. Cells were observed under a phase-contrast microscope. Original magnification, x100.

 
The number of viable RPE cells was not reduced within 48 hours when cells were infected with LacZ virus or mutant I{kappa}B virus, either with or without TNF-{alpha} treatment. In contrast, the number of T-98G cells infected to express mutant I{kappa}B was markedly decreased in a time-dependent manner, whereas the number of viable noninfected or LacZ-infected T-98G cells was unchanged (Fig. 5A) . To investigate further whether RPE cells undergo TNF-{alpha}–mediated cell death after NF-{kappa}B blockade, but at a slower rate than T-98G cells, the viable cell number was determined at 0, 24, 48, and 72 hours. Noninfected RPE cells or RPE cells infected with adenovirus were resistant to TNF-{alpha}–induced cell death at all time points, even after NF-{kappa}B blockade (Fig. 5B) .



View larger version (47K):
[in this window]
[in a new window]
  		FIGURE 5. Resistance to TNF-{alpha}–induced cell death in RPE cells that overexpress mutant I{kappa}B. (A) RPE cells and T-98G cells in triplicate wells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were treated with medium alone or TNF-{alpha} (1.1 x 103 U/mL) for varying times. Cell viability was evaluated by trypan blue exclusion assay. Cell Number represents live cells that excluded trypan blue. Results are expressed as the mean ± SD (n = 3). *P < 0.004 versus untreated cells in mutant I{kappa}B virus group; **P < 0.000005 versus untreated cells in mutant I{kappa}B virus group. (B) RPE cells in triplicate wells were infected with adenovirus containing LacZ or mutant I{kappa}B and then treated with medium alone or TNF-{alpha} (1.1 x 103 U/mL) for varying times 1 day after infection. Cell viability was evaluated by trypan blue exclusion assay. Cell Number represents live cells that excluded trypan blue. Results are expressed as the mean ± SD (n = 3).

 
An MOI of 10 in RPE cells produced an infection efficiency similar to that produced by an MOI of 300 in T-98G cells. To further confirm that the differential effect of TNF-{alpha} and NF-{kappa}B blockade on cell death was specific and not related to different MOIs in the two cell types, an additional experiment was performed.

At an MOI of 300, RPE cell morphology was altered in both the LacZ virus group and mutant I{kappa}B virus group. Some cells in both groups were rounded, detached from the plates, and floated in the medium. Surviving cells appear enlarged, elongated, and less densely packed. However, TNF-{alpha} did not further reduce the number of surviving adenovirus-infected cells compared with non–TNF-{alpha}–treated adenovirus-infected cells. In contrast, even at an MOI of 10, when the infection efficiency of T-98G cells was only 30%, TNF-{alpha} still induced significant cell death compared with cells that were not treated with TNF-{alpha} (Table 1) .


View this table:
[in this window]
[in a new window]
  		TABLE 1. The Effect of Adenovirus Transduction on TNF-{alpha}–Induced Cell Death

 
To evaluate the effect of NF-{kappa}B blockade on RPE cell apoptosis after cytokine stimulation, we measured caspase-3 activity, an early marker of apoptosis, in both RPE cells and T-98G cells. Caspase-3 was not activated in noninfected RPE cells, LacZ-expressing RPE cells, or RPE cells infected to express mutant I{kappa}B 8 hours after TNF-{alpha} treatment. However, caspase-3 activity was strongly induced in T-98G cells infected to express mutant I{kappa}B, but not in noninfected or LacZ-expressing T-98G cells after TNF-{alpha} treatment (Fig. 6) . Even at 6 hours, TNF-{alpha} significantly induced caspase-3 activity in T-98G cells infected to express mutant I{kappa}B compared to untreated group (P < 0.01) (not shown). IL-1ß had no effect on caspase-3 activity in T-98G cells infected to express mutant I{kappa}B (not shown).



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 6. Resistance to TNF-{alpha}–induced caspase-3 activity in RPE cells that overexpress mutant I{kappa}B. RPE cells and T-98G cells in triplicate wells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were treated with medium alone or TNF-{alpha} (1.1 x 103 U/mL) for 8 hours. Caspase-3 activity was measured by ELISA. Results are expressed as the mean ± SD (n = 3). *P < 0.00003 versus untreated T-98G cells in the mutant I{kappa}B virus group.

 
We next measured DNA fragmentation, a late marker of apoptosis, in RPE cells and T-98G cells to confirm further our observation that RPE cells, unlike T-98G cells, were resistant to TNF-{alpha}–induced apoptosis after NF-{kappa}B inhibition. Neither TNF-{alpha} nor IL-1ß induced DNA fragmentation in RPE cells infected with either LacZ or mutant I{kappa}B. In contrast, after TNF-{alpha} treatment for 8 hours, significant DNA fragmentation was detected in T-98G cells infected to express mutant I{kappa}B, but not in LacZ-expressing T-98G cells. Notably, IL-1ß did not cause DNA fragmentation in T-98G cells infected to express mutant I{kappa}B (Fig. 7) .



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 7. Resistance to TNF-{alpha}–induced DNA fragmentation in RPE cells that overexpress mutant I{kappa}B. RPE cells and T-98G cells in triplicate wells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were treated with medium alone, TNF-{alpha} (1.1 x 103 U/mL) or IL-1ß (5 U/mL) for 8 hours. DNA fragmentation was measured by ELISA. Results are expressed as the mean ± SD (n = 3). *P < 0.003 versus untreated cells in the mutant I{kappa}B virus group; **P < 0.00001 versus TNF-{alpha}–treated cells in the mutant I{kappa}B virus group.

 
To verify that RPE cells were truly resistant to TNF-{alpha}–induced apoptosis after NF-{kappa}B blockade and did not simply undergo apoptosis more slowly than T-98G cells, we repeated the RPE cell DNA fragmentation assay at 8, 24, 48, and 72 hours. In this experiment, DNA fragmentation in T-98G cells was used as a positive apoptosis control. DNA fragmentation could not be measured accurately in these cells at later time points, because of massive cell death. DNA fragmentation was not induced by TNF-{alpha} in RPE cells infected to express mutant I{kappa}B at any time points (Fig. 8) .



View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 8. Resistance to TNF-{alpha}–induced DNA fragmentation at various time points in RPE cells that overexpressed mutant I{kappa}B. RPE cells and T-98G cells in triplicate wells were infected with adenovirus containing mutant I{kappa}B. One day after infection, cells were treated with medium alone or TNF-{alpha} (1.1 x 103 U/mL). DNA fragmentation was measured by ELISA. Results are expressed as the mean ± SD (n = 3). *P < 0.001 versus untreated cells in mutant I{kappa}B virus group. (A) RPE cells; (B) T-98G cells.

 
Effect of NF-{kappa}B Activation on c-FLIP and c-IAP1 Expression
NF-{kappa}B regulates the expression of a number of genes whose products can inhibit apoptosis.33 c-FLIP is a protein that is thought to be an important determinant of cell survival. It competes with caspase-8 binding to FADD and thereby blocks apoptosis at the apex of the caspase cascade.17 34 We determined whether RPE cell c-FLIP expression could account for RPE cell resistance to TNF-{alpha}–driven apoptosis after NF-{kappa}B blockade. TNF-{alpha} upregulated the 55-kDa long FLIP (FLIPL) form and short FLIP (FLIPS) form expression in noninfected or LacZ-expressing RPE cells. NF-{kappa}B inhibition abolished upregulation of cellular long and short c-FLIP protein. Thus c-FLIP upregulation by TNF-{alpha} could help to explain why RPE cells are resistant to TNF-{alpha}–induced apoptosis. However, the complete blockade of c-FLIP induction by mutant I{kappa}B indicates that c-FLIP does not account for RPE cell resistance to apoptosis after TNF-{alpha} stimulation and NF-{kappa}B blockade (Fig. 9) .



View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 9. Blockade of c-FLIP protein expression by mutant I{kappa}B overexpression. RPE cells in duplicate wells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were treated with medium alone or TNF-{alpha} (1.1 x 103 U/mL) for 6 hours, and cytoplasmic proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane for Western blot analysis. (A) Western blot probed with antibody to c-FLIP. Bands at 55 kDa correspond to the long c-FLIP form and bands at 28 kDa to the short c-FLIP form. The relative quantity of long and short c-FLIP protein forms, determined by densitometry, is shown separately below each lane. (B) Blot in (A) stripped and reprobed with antibody to ß-catenin, a control for gel loading. The relative quantity of ß-catenin protein is shown below each lane.

 
To investigate further the mechanism underlying the survival of RPE cells in response to TNF-{alpha}, we examined the expression of c-IAP1, another important cell survival factor.19 First, we examined the kinetics of c-IAP1 expression in noninfected RPE cells in the presence of TNF-{alpha} or IL-1ß. The expression of c-IAP1 protein, however, was not affected by TNF-{alpha} or IL-1ß treatment at any time period tested (Fig. 10A) . We investigated the effect of NF-{kappa}B inhibition on TNF-{alpha}–mediated c-IAP1 induction by examining c-IAP protein expression in RPE cells after TNF-{alpha} treatment. NF-{kappa}B inhibition failed to block c-IAP1 expression after 6 hours in the presence or absence of TNF-{alpha} treatment (Fig. 10B) .



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 10. c-IAP1 protein expression after NF-{kappa}B blockade. Noninfected RPE cells were treated with TNF-{alpha} (1.1 x 103 U/mL) or IL-1ß (5 U/mL) for various times. In addition, RPE cells in duplicate wells were infected with adenovirus containing LacZ or mutant I{kappa}B. One day after infection, cells were treated with medium alone, or TNF-{alpha} (1.1 x 103 U/mL). Cytoplasmic proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane for Western blot analysis. (A) Kinetics of the c-IAP1 expression after TNF-{alpha} or IL-1ß treatment for various times. Bands at 68 kDa correspond to c-IAP1. The relative quantity of c-IAP1 proteins, determined by densitometry, is shown separately below each lane. (B) Effect of mutant I{kappa}B overexpression on TNF-{alpha}–mediated c-IAP1 expression. Cells were treated with TNF-{alpha} for 6 hours. Bands at 68 kDa correspond to c-IAP1. The relative quantity of c-IAP1 proteins, determined by densitometry, is shown separately below each lane.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In the present study, a mutant I{kappa}B protein expressed in human RPE cells by viral transduction was resistant to cytokine-stimulated degradation and inhibited cytokine-induced NF-{kappa}B transcriptional activity. RPE cells were resistant to TNF-{alpha}–induced cell death, caspase-3 activity, and DNA fragmentation, even after NF-{kappa}B activation was specifically blocked by mutant I{kappa}B. IL-1ß had no effect on apoptosis in RPE cells after NF-{kappa}B suppression. We identified c-FLIP and c-IAP1 as antiapoptotic factors that could help to protect RPE cells from TNF-{alpha}–induced apoptosis and c-IAP1 as a protein that may promote RPE cell survival after NF-{kappa}B blockade.

We used T-98G cells as a positive control for TNF-{alpha}–induced apoptosis after NF-{kappa}B blockade. Our initial experiments were conducted to determine an MOI for T-98G cells that would provide transgene expression efficiency similar to that obtained with an MOI of 10 in RPE cells. Our results, which indicated an optimal MOI of 300 in T-98G cells, are similar to those reported previously.23 The reason for the more efficient transgene transduction in RPE cells than in T-98G cells is unknown.

The effect of NF-{kappa}B activation on apoptosis is very cell-type specific. Depending on the cell, NF-{kappa}B may have an antiapoptotic or proapoptotic effect.33 35 36 37 38 39 Constitutive NF-{kappa}B activity, seen in Hodgkin’s disease cells, protects the cells against apoptosis, and NF-{kappa}B inhibition leads to cell death.40 In many cells, NF-{kappa}B activation protects against TNF-{alpha}–driven apoptosis, and NF-{kappa}B blockade causes TNF-{alpha}–induced cell death.17 18 19 20 For example, human glioma cells are relatively resistant to apoptotic stimuli.41 Like RPE cells, T-98G and U251 glioma cells express TNF-R1 receptors26 42 and do not undergo apoptosis when treated with TNF-{alpha} alone; however, as indicated earlier, these cells undergo apoptosis after TNF-{alpha} exposure when they are first infected with an I{kappa}B deletion mutant.23 43 In contrast, as shown in the current study, RPE cells do not undergo TNF-{alpha}–mediated apoptosis after NF-{kappa}B blockade. Similarly, human HCT116 colon carcinoma cells, OVCAR-3 ovarian carcinoma cells, and HPB lymphoid T cells are resistant to TNF-{alpha}–stimulated apoptosis after NF-{kappa}B inhibition.44 In other experimental systems—for example, after serum withdrawal from 293 cells and in Sindbis virus–infected cells during glutamate-induced neuronal cell cytotoxicity, NF-{kappa}B activation is necessary for initiation of apoptosis.36 37 38 39 The varying apoptotic response to NF-{kappa}B activation may provide organ-specific cell survival or death after physiological stimuli and may contribute to pathologic cell survival or death in diseases such as cancer and PVR.

We originally hypothesized that NF-{kappa}B blockade might be a potentially valuable PVR treatment strategy by virtue of its effect as an inducer of RPE cells apoptosis, and its role as an inhibitor of inflammatory cytokine gene expression. The results of the present experiments suggest that NF-{kappa}B blockade would not induce RPE cell apoptosis. Regardless, it is very likely that NF-{kappa}B inhibition would downregulate multiple cytokines thought to be important in the initiation and perpetuation of PVR.7 8 10 11 Nonetheless, because NF-{kappa}B plays a central role as a transcription regulator of multiple genes, there may be unintended and/or unwanted gene transcription effects. NF-{kappa}B blockade as a method to inhibit PVR warrants further investigation.

In the present study, the antiapoptotic factor c-FLIP was upregulated by TNF-{alpha} in an NF-{kappa}B–dependent manner. Similarly, other investigators have demonstrated that NF-{kappa}B activation mediates c-FLIP expression.17 45 c-FLIP is a potent antiapoptotic factor that binds to the protein Fas-associated death domain (FADD).46 Two splice variants of c-FLIP have been identified.47 48 The full-length 55-kDa c-FLIP form, c-FLIPL, has structural homology to caspase-8, and contains two death effector domains (DEDs) that bind to FADD and an inactive caspaselike domain. An alternately spliced short c-FLIP form, c-FLIPS, contains only the two DEDs. Both forms inhibit apoptosis, although the relative antiapoptotic potency of the two forms depends on the specific cell.45 49 It is thought that the c-FLIP/procaspase-8 ratio determines whether apoptosis is activated through the effector caspases downstream of caspase-8.46 We found that TNF-{alpha} markedly enhanced both the c-FLIPL and c-FLIPS RPE protein levels. Accordingly, we hypothesize that c-FLIP may be an important factor that protects RPE cells from TNF-{alpha}–induced cell death. NF-{kappa}B blockade completely abolished the TNF-{alpha}–stimulated c-FLIPL and c-FLIPS upregulation. However, under these conditions, RPE cells were still resistant to TNF-{alpha}–mediated cell death. Thus, c-FLIP expression cannot fully explain RPE cell resistance to TNF-{alpha}–mediated RPE cell apoptosis.

In our experiments, cultured human RPE cells expressed another important antiapoptotic factor, c-IAP, which inhibits apoptosis by binding directly to effector caspases such as caspase-3 and -7, thereby inactivating them.50 51 In addition, c-IAP1, along with c-IAP2, TRAF-1, and TRAF-2, is recruited to death domains on TNF receptor 1 to form the death-inducing signaling complex (DISC).50 51 This complex functions to inhibit apoptosis at the apex of the TNF-{alpha}/caspase–signaling cascade. Thus, c-IAP, along with c-FLIP, could serve to protect RPE cells from TNF-{alpha}–mediated cell death. In contrast to c-FLIP, high c-IAP levels were expressed under basal conditions, and levels were not influenced significantly by TNF-{alpha}–stimulation or NF-{kappa}B blockade. The regulation of cellular c-IAP is very cell-type specific. In several cell types, c-IAP expression is enhanced by NF-{kappa}B, an effect that is prevented by NF-{kappa}B blockade.19 In many other cells, as in RPE cells, c-IAP protein is expressed constitutively, and levels are not influenced by NF-{kappa}B activation.52 53 Constitutive c-IAP1 protein expressed by RPE cells could help to explain why RPE cells are resistant to TNF-{alpha}–mediated apoptosis, despite NF-{kappa}B blockade.

Our results indicate that RPE cells are resistant to TNF-{alpha}–mediated cell death, both by NF-{kappa}B–dependent and NF-{kappa}B–independent mechanisms. In PVR, RPE cells that have left their normal monolayer survive for extended times in the subretinal space, in the vitreous cavity, and on the retinal surface and undersurface. Experiments are currently under way in our laboratory to clarify further the role of antiapoptotic factors such as c-FLIP and c-IAP1 in PVR.


   Acknowledgements
 
The authors thank Jessica Wiser for help with grading of cells stained with X-gal.


   Footnotes
 
4 Present address: National Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, North Carolina. Back

Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 2003.

Supported by National Eye Institute Grant R01 EY9106 (GJJ) and Core Grant P30EY05722.

Submitted for publication July 29, 2003; revised October 27, 2003; accepted December 11, 2003.

Disclosure: P. Yang, None; B.S. McKay, None; J.B. Allen, None; G.J. Jaffe, None

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Glenn J. Jaffe, Department of Ophthalmology, Duke University Eye Center, Durham, NC 27710; jaffe001{at}mc.duke.edu.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79:953–960.[Free Full Text]
  2. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3–18.[CrossRef][ISI][Medline][Order article via Infotrieve]
  3. Kirchhof B, Sorgente N. Pathogenesis of proliferative vitreoretinopathy: modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev Ophthalmol. 1989;16:1–53.[Medline][Order article via Infotrieve]
  4. Hueber A, Aduckathil S, Kociok N, et al. Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2002;240:551–556.[ISI][Medline][Order article via Infotrieve]
  5. Dunaief JL, Dentchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol. 2002;120:1435–1442.[Abstract/Free Full Text]
  6. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov. 2002;1:111–121.[CrossRef][ISI][Medline][Order article via Infotrieve]
  7. Armstrong D, Augustin aJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor {alpha} in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 1998;212:410–414.[CrossRef][ISI][Medline][Order article via Infotrieve]
  8. Limb GA, Alam A, Earley O, et al. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res. 1994;13:791–798.[ISI][Medline][Order article via Infotrieve]
  9. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891–1898.[Abstract/Free Full Text]
  10. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol. 1999;83:1296–1299.[Abstract/Free Full Text]
  11. Limb GA, Little BC, Meager A, et al. Cytokines in proliferative vitreoretinopathy. Eye. 1991;5:686–693.
  12. Chaum E. Proliferative vitreoretinopathy. Int Ophthalmol Clin. 1995;35:163–173.[CrossRef][ISI][Medline][Order article via Infotrieve]
  13. Weller M, Heimann K, Wiedemann P. The pathogenesis of vitreoretinal proliferation and traction: a working hypothesis. Med Hypotheses. 1990;31:157–159.[CrossRef][ISI][Medline][Order article via Infotrieve]
  14. Jin M, He S, Worpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-{alpha}. Invest Ophthalmol Vis Sci. 2000;41:4324–4332.[Abstract/Free Full Text]
  15. Burke JM. Stimulation of DNA synthesis in human and bovine RPE by peptide growth factors: the response to TNF-{alpha} and EGF is dependent upon culture density. Curr Eye Res. 1989;8:1279–1286.[ISI][Medline][Order article via Infotrieve]
  16. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405–455.[CrossRef][ISI][Medline][Order article via Infotrieve]
  17. Xiao CW, Yan X, Li Y, Reddy SA, Tsang BK. Resistance of human ovarian cancer cells to tumor necrosis factor {alpha} is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology. 2003;144:623–630.[Abstract/Free Full Text]
  18. Stehlik C, De Martin R, Kumabashiri I, et al. Nuclear factor (NF)-{kappa}B-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor {alpha}-induced apoptosis. J Exp Med. 1998;188:211–216.[Abstract/Free Full Text]
  19. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-{kappa}B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–1683.[Abstract/Free Full Text]
  20. Chen C, Edelstein LC, Gelinas C. The Rel/NF-{kappa}B family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687–2695.[Abstract/Free Full Text]
  21. Beg AA, Baltimore D. An essential role for NF-{kappa}B in preventing TNF-{alpha}-induced cell death. Science. 1996;274:782–784.[Abstract/Free Full Text]
  22. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-{alpha}-induced apoptosis by NF-{kappa}B. Science. 1996;274:787–789.[Abstract/Free Full Text]
  23. Shinoura N, Yamamoto N, Yoshida Y, et al. Adenovirus-mediated gene transduction of I{kappa}B or I{kappa}B plus Bax gene drastically enhances tumor necrosis factor (TNF)-induced apoptosis in human gliomas. Jpn J Cancer Res. 2000;91:41–51.[CrossRef][ISI][Medline][Order article via Infotrieve]
  24. Hirahashi J, Takayanagi A, Hishikawa K, et al. Overexpression of truncated I kappa B alpha potentiates TNF-{alpha}-induced apoptosis in mesangial cells. Kidney Int. 2000;57:959–968.[CrossRef][ISI][Medline][Order article via Infotrieve]
  25. Jaffe GJ, Earnest K, Fulcher S, Lui GM, Houston LL. Antitransferrin receptor immunotoxin inhibits proliferating human retinal pigment epithelial cells. Arch Ophthalmol. 1990;108:1163–1168.[Abstract]
  26. Morgavi P, Cimoli G, Ottoboni C, et al. Sensitization of human glioblastoma T98G cells to VP16 and VM26 by human tumor necrosis factor. Anticancer Res. 1995;15:1423–1428.[ISI][Medline][Order article via Infotrieve]
  27. Jobin C, Panja A, Hellerbrand C, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol. 1998;160:410–418.[Abstract/Free Full Text]
  28. Wang XC, Jobin C, Allen JB, Roberts WL, Jaffe GJ. Suppression of NF-{kappa}B–dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest Ophthalmol Vis Sci. 1999;40:477–486.[Abstract/Free Full Text]
  29. Yang P, Mckay BS, Allen JB, Roberts WL, Jaffe GJ. Effect of mutant on cytokine-induced activation of NF-{kappa}B in cultured human RPE cells. Invest Ophthalmol Vis Sci. 2003;44:1339–1347.[Abstract/Free Full Text]
  30. Watanabe M, Hitomi M, Van Der Wee K, et al. The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc Microanal. 2002;8:375–391.[CrossRef][ISI][Medline][Order article via Infotrieve]
  31. Stadelmann C, Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res. 2000;301:19–31.[CrossRef][ISI][Medline][Order article via Infotrieve]
  32. Waltzer L, Bienz M. The control of ß-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev. 1999;18:231–246.[CrossRef][ISI][Medline][Order article via Infotrieve]
  33. Karin M, Lin A. NF-{kappa}B at the crossroads of life and death. Nat Immunol. 2002;3:221–227.[CrossRef][ISI][Medline][Order article via Infotrieve]
  34. Cottet S, Dupraz P, Hamburger F, et al. cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells. Diabetes. 2002;51:1805–1814.[Abstract/Free Full Text]
  35. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-{kappa}B. J Clin Invest. 2001;107:241–246.[CrossRef][ISI][Medline][Order article via Infotrieve]
  36. Baichwal VR, Baeuerle PA. Activate NF-{kappa}B or die?. Curr Biol. 1997;7:R94–R96.[CrossRef][ISI][Medline][Order article via Infotrieve]
  37. Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K. Bcl-2 down-regulates the activity of transcription factor NF-kappa B induced upon apoptosis. J Cell Biol. 1996;134:13–23.[Abstract/Free Full Text]
  38. Lin KI, Lee SH, Narayanan R, et al. Thiol agents and Bcl-2 identify an alpha virus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. J Cell Biol. 1995;131:1149–1161.[Abstract/Free Full Text]
  39. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-{kappa}B activation. Science. 1996;274:1383–1385.[Abstract/Free Full Text]
  40. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest. 1997;100:2961–2969.[ISI][Medline][Order article via Infotrieve]
  41. Otsuka G, Nagaya T, Saito K, et al. Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res. 1999;59:4446–4452.[Abstract/Free Full Text]
  42. Kato T, Sawamura Y, Tada M, et al. p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Neurol Med Chir (Tokyo). 1995;35:567–574.[Medline][Order article via Infotrieve]
  43. Shinoura N, Yamamoto N, Yoshida Y, et al. Adenovirus-mediated transfer of caspase-8 in combination with superrepressor of NF-{kappa}B drastically induced apoptosis in gliomas. Biochem Biophys Res Commun. 2000;271:544–552.[CrossRef][ISI][Medline][Order article via Infotrieve]
  44. Bentires-Alj M, Hellin AC, Ameyar M, et al. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res. 1999;59:811–815.[Abstract/Free Full Text]
  45. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-{kappa}B signals induce the expression of c-FLIP. Mol Cell Biol. 2001;21:5299–5305.[Abstract/Free Full Text]
  46. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol. 2001;21:8247–8254.[Free Full Text]
  47. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol. 1998;10:552–558.[CrossRef][ISI][Medline][Order article via Infotrieve]
  48. Wallach D. Apoptosis: placing death under control. Nature. 1997;388:123,125–126.
  49. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-{kappa}B inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001;21:3964–3973.[Abstract/Free Full Text]
  50. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3:401–410.[CrossRef][ISI][Medline][Order article via Infotrieve]
  51. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev. 1999;13:239–252.[Free Full Text]
  52. Aota K, Azuma M, Tamatani T, et al. Stable inhibition of NF-kappa B in salivary gland cells does not enhance sensitivity to TNF-{alpha}-induced apoptosis due to upregulation of TRAF-1 expression. Exp Cell Res. 2002;276:111–119.[CrossRef][ISI][Medline][Order article via Infotrieve]
  53. Bergmann MW, Loser P, Dietz R, Von Harsdorf R. Effect of NF-kappa B Inhibition on TNF-{alpha}-induced apoptosis and downstream pathways in cardiomyocytes. J Mol Cell Cardiol. 2001;33:1223–1232.